Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8TE4F
|
|||
| Drug Name |
AMXI 5001
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1/2 | [1] | |
| Company |
AtlasMedx
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Microtubule polymerization (MicroTu poly) | Target Info | Inhibitor | [2] |
| Poly [ADP-ribose] polymerase 1 (PARP1) | Target Info | Inhibitor | [2] | |
| Poly [ADP-ribose] polymerase 2 (PARP2) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Base excision repair | |||
| NF-kappa B signaling pathway | ||||
| Apoptosis | ||||
| Necroptosis | ||||
| Panther Pathway | FAS signaling pathway | |||
| Pathway Interaction Database | Integrin-linked kinase signaling | |||
| Caspase Cascade in Apoptosis | ||||
| Notch-mediated HES/HEY network | ||||
| Reactome | Dual Incision in GG-NER | |||
| WikiPathways | FAS pathway and Stress induction of HSP regulation | |||
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | ||||
| Nanoparticle triggered regulated necrosis | ||||
| Corticotropin-releasing hormone | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04503265) A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.